Investing.com - Fusion Pharma (NASDAQ: FUSN) reported first quarter EPS of $-0.400, $0.03 worse than the analyst estimate of $-0.370. Revenue for the quarter came in at $25K versus the consensus estimate of $126.38K.
Fusion Pharma's stock price closed at $21.42. It is up 85.130% in the last 3 months and up 393.090% in the last 12 months.
Fusion Pharma saw 2 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Fusion Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Fusion Pharma's Financial Health score is "fair performance".
Check out Fusion Pharma's recent earnings performance, and Fusion Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar